Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer
In order to find novel noninvasive biomarkers with high accuracy for the screening of early-stage non-small cell lung cancer (NSCLC), we investigate the predictive power of 5 microRNAs (miR-20a, miR-145, miR-21, miR223 and miR-221) as potential biomarkers in early-stage NSCLC. In training set, 25 ea...
Gespeichert in:
| Veröffentlicht in: | Respiratory research 2014-11, Vol.15 (1), p.149-149, Article 149 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 149 |
|---|---|
| container_issue | 1 |
| container_start_page | 149 |
| container_title | Respiratory research |
| container_volume | 15 |
| creator | Geng, Qing Fan, Tao Zhang, Boyou Wang, Wei Xu, Yao Hu, Hao |
| description | In order to find novel noninvasive biomarkers with high accuracy for the screening of early-stage non-small cell lung cancer (NSCLC), we investigate the predictive power of 5 microRNAs (miR-20a, miR-145, miR-21, miR223 and miR-221) as potential biomarkers in early-stage NSCLC.
In training set, 25 early-stage NSCLC patients and 25 matched healthy controls are included to assess the miRNA expression profile between early-stage NSCLC patients and healthy controls by real-time RT-PCR. We found that five of these miRNAs (miR-20a, miR-223, miR-21, miR-221 and miR-145) levels in NSCLC patients were significantly dysregulated compared with the healthy groups and thus were selected to validation set. Therefore, a validation experiment was further performed to investigate the potential predictive power of these five miRNAs based on 126 early-stage NSCLC patients, 42 NCPD patients and 60 healthy controls. The receiver operating characteristic (ROC) curves were generated for the five miRNAs.
ROC curve analyses suggested that these five plasma miRNAs could be promising biomarkers for NSCLC, with relatively high AUC values as follows: miR-20a, 0.89 with 95% CI of [0.85-0.93]; miR-223, 0.94 with 95% CI of [0.91-0.96]; miR-21, 0.77 with 95% CI of [0.71-0.83]; miR-155, 0.92 with 95% CI of [0.89-0.96]; miR-145, 0.77 with 95% CI of [0.71-0.83]. Stratified analyses indicated that plasma miR-20a, miR-223, miR-21 and miR-145 showed better predictive value in smokers than in non-smokers, while miR-155 might be more suitable for non-smokers. In addition, all of these five miRNAs could differentiate NSCLC from controls with a higher accuracy in advanced stage and squamous carcinoma subgroups.
In conclusion, our study suggested that five plasma miRNAs (miR-20a, miR-145, miR-21, miR-223 and miR-221) can be used as promising biomarkers in early screening of NSCLC. Nevertheless, further validation and optimizing improvement should be performed on larger sample to confirm our results. |
| doi_str_mv | 10.1186/s12931-014-0149-3 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4248445</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A539614899</galeid><sourcerecordid>A539614899</sourcerecordid><originalsourceid>FETCH-LOGICAL-c560t-74554a90c0b533259095acfffc1990d43a52dc0ae5a02ea9f382d76f31f81fe93</originalsourceid><addsrcrecordid>eNptUl1rFDEUDaLYWv0BvkjAF1-m5nNm8iIspbVCURAF38LdzM2aOpOsyc5C_70Ztq2tSLhJSM45yUkOIa85O-W8b98XLozkDeNqKdPIJ-SYq1Y3xsgfTx_Mj8iLUq4Z413f6efkSGglOOPsmAwXYY90Ci6nr59XhYZItyOUCSgUGtMeR7oOaYL8C3OhPmVaXEaMIW5o8hQhjzdN2cEGKzo2lTiO1GHtxrlCHESH-SV55mEs-Op2PCHfL86_nV02V18-fjpbXTVOt2zXdEprBYY5ttZSCm2Y0eC8944bwwYlQYvBMUANTCAYL3sxdK2X3Pfco5En5MNBdzuvJxwcxl2G0W5zqAZubIJgH-_E8NNu0t4qoXqldBV4dyuQ0-8Zy85OoSxuIGKai-Vt10rZa8Yq9O0_0Os051jtVZQwqjOd7v6iNjCiDdGneq5bRO1KS9Ny1Zvl3qf_QdU2YP2ZFNGHuv6IwA-E-m2lZPT3HjmzSzTsIRq2xmIpY2XlvHn4OPeMuyzIP-sUs7E</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1629479757</pqid></control><display><type>article</type><title>Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer</title><source>Open Access: PubMed Central</source><source>Springer Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>SpringerLink_现刊</source><source>Free E-Journal (出版社公開部分のみ）</source><creator>Geng, Qing ; Fan, Tao ; Zhang, Boyou ; Wang, Wei ; Xu, Yao ; Hu, Hao</creator><creatorcontrib>Geng, Qing ; Fan, Tao ; Zhang, Boyou ; Wang, Wei ; Xu, Yao ; Hu, Hao</creatorcontrib><description>In order to find novel noninvasive biomarkers with high accuracy for the screening of early-stage non-small cell lung cancer (NSCLC), we investigate the predictive power of 5 microRNAs (miR-20a, miR-145, miR-21, miR223 and miR-221) as potential biomarkers in early-stage NSCLC.
In training set, 25 early-stage NSCLC patients and 25 matched healthy controls are included to assess the miRNA expression profile between early-stage NSCLC patients and healthy controls by real-time RT-PCR. We found that five of these miRNAs (miR-20a, miR-223, miR-21, miR-221 and miR-145) levels in NSCLC patients were significantly dysregulated compared with the healthy groups and thus were selected to validation set. Therefore, a validation experiment was further performed to investigate the potential predictive power of these five miRNAs based on 126 early-stage NSCLC patients, 42 NCPD patients and 60 healthy controls. The receiver operating characteristic (ROC) curves were generated for the five miRNAs.
ROC curve analyses suggested that these five plasma miRNAs could be promising biomarkers for NSCLC, with relatively high AUC values as follows: miR-20a, 0.89 with 95% CI of [0.85-0.93]; miR-223, 0.94 with 95% CI of [0.91-0.96]; miR-21, 0.77 with 95% CI of [0.71-0.83]; miR-155, 0.92 with 95% CI of [0.89-0.96]; miR-145, 0.77 with 95% CI of [0.71-0.83]. Stratified analyses indicated that plasma miR-20a, miR-223, miR-21 and miR-145 showed better predictive value in smokers than in non-smokers, while miR-155 might be more suitable for non-smokers. In addition, all of these five miRNAs could differentiate NSCLC from controls with a higher accuracy in advanced stage and squamous carcinoma subgroups.
In conclusion, our study suggested that five plasma miRNAs (miR-20a, miR-145, miR-21, miR-223 and miR-221) can be used as promising biomarkers in early screening of NSCLC. Nevertheless, further validation and optimizing improvement should be performed on larger sample to confirm our results.</description><identifier>ISSN: 1465-993X</identifier><identifier>ISSN: 1465-9921</identifier><identifier>EISSN: 1465-993X</identifier><identifier>EISSN: 1465-9921</identifier><identifier>DOI: 10.1186/s12931-014-0149-3</identifier><identifier>PMID: 25421010</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Accuracy ; Analysis ; Area Under Curve ; Biological markers ; Biomarkers ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - genetics ; Cancer ; Carcinoma, Non-Small-Cell Lung - blood ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - pathology ; Care and treatment ; Case-Control Studies ; Cell growth ; Chronic obstructive pulmonary disease ; Comparative analysis ; Diagnosis ; Disease ; Double-Blind Method ; Female ; Gene Expression Profiling - methods ; Genetic Testing - methods ; Humans ; Lung cancer ; Lung cancer, Non-small cell ; Lung Neoplasms - blood ; Lung Neoplasms - genetics ; Lung Neoplasms - pathology ; Male ; Materials selection ; Medical imaging ; MicroRNA ; MicroRNAs ; MicroRNAs - blood ; MicroRNAs - genetics ; Middle Aged ; Mortality ; Neoplasm Staging ; Plasma ; Predictive Value of Tests ; Reproducibility of Results ; Risk Factors ; ROC Curve ; Studies ; Surgery ; Thoracic surgery</subject><ispartof>Respiratory research, 2014-11, Vol.15 (1), p.149-149, Article 149</ispartof><rights>COPYRIGHT 2014 BioMed Central Ltd.</rights><rights>2014 Geng et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.</rights><rights>Geng et al.; licensee BioMed Central Ltd. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c560t-74554a90c0b533259095acfffc1990d43a52dc0ae5a02ea9f382d76f31f81fe93</citedby><cites>FETCH-LOGICAL-c560t-74554a90c0b533259095acfffc1990d43a52dc0ae5a02ea9f382d76f31f81fe93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248445/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248445/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25421010$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Geng, Qing</creatorcontrib><creatorcontrib>Fan, Tao</creatorcontrib><creatorcontrib>Zhang, Boyou</creatorcontrib><creatorcontrib>Wang, Wei</creatorcontrib><creatorcontrib>Xu, Yao</creatorcontrib><creatorcontrib>Hu, Hao</creatorcontrib><title>Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer</title><title>Respiratory research</title><addtitle>Respir Res</addtitle><description>In order to find novel noninvasive biomarkers with high accuracy for the screening of early-stage non-small cell lung cancer (NSCLC), we investigate the predictive power of 5 microRNAs (miR-20a, miR-145, miR-21, miR223 and miR-221) as potential biomarkers in early-stage NSCLC.
In training set, 25 early-stage NSCLC patients and 25 matched healthy controls are included to assess the miRNA expression profile between early-stage NSCLC patients and healthy controls by real-time RT-PCR. We found that five of these miRNAs (miR-20a, miR-223, miR-21, miR-221 and miR-145) levels in NSCLC patients were significantly dysregulated compared with the healthy groups and thus were selected to validation set. Therefore, a validation experiment was further performed to investigate the potential predictive power of these five miRNAs based on 126 early-stage NSCLC patients, 42 NCPD patients and 60 healthy controls. The receiver operating characteristic (ROC) curves were generated for the five miRNAs.
ROC curve analyses suggested that these five plasma miRNAs could be promising biomarkers for NSCLC, with relatively high AUC values as follows: miR-20a, 0.89 with 95% CI of [0.85-0.93]; miR-223, 0.94 with 95% CI of [0.91-0.96]; miR-21, 0.77 with 95% CI of [0.71-0.83]; miR-155, 0.92 with 95% CI of [0.89-0.96]; miR-145, 0.77 with 95% CI of [0.71-0.83]. Stratified analyses indicated that plasma miR-20a, miR-223, miR-21 and miR-145 showed better predictive value in smokers than in non-smokers, while miR-155 might be more suitable for non-smokers. In addition, all of these five miRNAs could differentiate NSCLC from controls with a higher accuracy in advanced stage and squamous carcinoma subgroups.
In conclusion, our study suggested that five plasma miRNAs (miR-20a, miR-145, miR-21, miR-223 and miR-221) can be used as promising biomarkers in early screening of NSCLC. Nevertheless, further validation and optimizing improvement should be performed on larger sample to confirm our results.</description><subject>Accuracy</subject><subject>Analysis</subject><subject>Area Under Curve</subject><subject>Biological markers</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Cancer</subject><subject>Carcinoma, Non-Small-Cell Lung - blood</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Care and treatment</subject><subject>Case-Control Studies</subject><subject>Cell growth</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Comparative analysis</subject><subject>Diagnosis</subject><subject>Disease</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Gene Expression Profiling - methods</subject><subject>Genetic Testing - methods</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>Lung cancer, Non-small cell</subject><subject>Lung Neoplasms - blood</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Materials selection</subject><subject>Medical imaging</subject><subject>MicroRNA</subject><subject>MicroRNAs</subject><subject>MicroRNAs - blood</subject><subject>MicroRNAs - genetics</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Neoplasm Staging</subject><subject>Plasma</subject><subject>Predictive Value of Tests</subject><subject>Reproducibility of Results</subject><subject>Risk Factors</subject><subject>ROC Curve</subject><subject>Studies</subject><subject>Surgery</subject><subject>Thoracic surgery</subject><issn>1465-993X</issn><issn>1465-9921</issn><issn>1465-993X</issn><issn>1465-9921</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptUl1rFDEUDaLYWv0BvkjAF1-m5nNm8iIspbVCURAF38LdzM2aOpOsyc5C_70Ztq2tSLhJSM45yUkOIa85O-W8b98XLozkDeNqKdPIJ-SYq1Y3xsgfTx_Mj8iLUq4Z413f6efkSGglOOPsmAwXYY90Ci6nr59XhYZItyOUCSgUGtMeR7oOaYL8C3OhPmVaXEaMIW5o8hQhjzdN2cEGKzo2lTiO1GHtxrlCHESH-SV55mEs-Op2PCHfL86_nV02V18-fjpbXTVOt2zXdEprBYY5ttZSCm2Y0eC8944bwwYlQYvBMUANTCAYL3sxdK2X3Pfco5En5MNBdzuvJxwcxl2G0W5zqAZubIJgH-_E8NNu0t4qoXqldBV4dyuQ0-8Zy85OoSxuIGKai-Vt10rZa8Yq9O0_0Os051jtVZQwqjOd7v6iNjCiDdGneq5bRO1KS9Ny1Zvl3qf_QdU2YP2ZFNGHuv6IwA-E-m2lZPT3HjmzSzTsIRq2xmIpY2XlvHn4OPeMuyzIP-sUs7E</recordid><startdate>20141125</startdate><enddate>20141125</enddate><creator>Geng, Qing</creator><creator>Fan, Tao</creator><creator>Zhang, Boyou</creator><creator>Wang, Wei</creator><creator>Xu, Yao</creator><creator>Hu, Hao</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20141125</creationdate><title>Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer</title><author>Geng, Qing ; Fan, Tao ; Zhang, Boyou ; Wang, Wei ; Xu, Yao ; Hu, Hao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c560t-74554a90c0b533259095acfffc1990d43a52dc0ae5a02ea9f382d76f31f81fe93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Accuracy</topic><topic>Analysis</topic><topic>Area Under Curve</topic><topic>Biological markers</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Cancer</topic><topic>Carcinoma, Non-Small-Cell Lung - blood</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Care and treatment</topic><topic>Case-Control Studies</topic><topic>Cell growth</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Comparative analysis</topic><topic>Diagnosis</topic><topic>Disease</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Gene Expression Profiling - methods</topic><topic>Genetic Testing - methods</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>Lung cancer, Non-small cell</topic><topic>Lung Neoplasms - blood</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Materials selection</topic><topic>Medical imaging</topic><topic>MicroRNA</topic><topic>MicroRNAs</topic><topic>MicroRNAs - blood</topic><topic>MicroRNAs - genetics</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Neoplasm Staging</topic><topic>Plasma</topic><topic>Predictive Value of Tests</topic><topic>Reproducibility of Results</topic><topic>Risk Factors</topic><topic>ROC Curve</topic><topic>Studies</topic><topic>Surgery</topic><topic>Thoracic surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Geng, Qing</creatorcontrib><creatorcontrib>Fan, Tao</creatorcontrib><creatorcontrib>Zhang, Boyou</creatorcontrib><creatorcontrib>Wang, Wei</creatorcontrib><creatorcontrib>Xu, Yao</creatorcontrib><creatorcontrib>Hu, Hao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Respiratory research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Geng, Qing</au><au>Fan, Tao</au><au>Zhang, Boyou</au><au>Wang, Wei</au><au>Xu, Yao</au><au>Hu, Hao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer</atitle><jtitle>Respiratory research</jtitle><addtitle>Respir Res</addtitle><date>2014-11-25</date><risdate>2014</risdate><volume>15</volume><issue>1</issue><spage>149</spage><epage>149</epage><pages>149-149</pages><artnum>149</artnum><issn>1465-993X</issn><issn>1465-9921</issn><eissn>1465-993X</eissn><eissn>1465-9921</eissn><abstract>In order to find novel noninvasive biomarkers with high accuracy for the screening of early-stage non-small cell lung cancer (NSCLC), we investigate the predictive power of 5 microRNAs (miR-20a, miR-145, miR-21, miR223 and miR-221) as potential biomarkers in early-stage NSCLC.
In training set, 25 early-stage NSCLC patients and 25 matched healthy controls are included to assess the miRNA expression profile between early-stage NSCLC patients and healthy controls by real-time RT-PCR. We found that five of these miRNAs (miR-20a, miR-223, miR-21, miR-221 and miR-145) levels in NSCLC patients were significantly dysregulated compared with the healthy groups and thus were selected to validation set. Therefore, a validation experiment was further performed to investigate the potential predictive power of these five miRNAs based on 126 early-stage NSCLC patients, 42 NCPD patients and 60 healthy controls. The receiver operating characteristic (ROC) curves were generated for the five miRNAs.
ROC curve analyses suggested that these five plasma miRNAs could be promising biomarkers for NSCLC, with relatively high AUC values as follows: miR-20a, 0.89 with 95% CI of [0.85-0.93]; miR-223, 0.94 with 95% CI of [0.91-0.96]; miR-21, 0.77 with 95% CI of [0.71-0.83]; miR-155, 0.92 with 95% CI of [0.89-0.96]; miR-145, 0.77 with 95% CI of [0.71-0.83]. Stratified analyses indicated that plasma miR-20a, miR-223, miR-21 and miR-145 showed better predictive value in smokers than in non-smokers, while miR-155 might be more suitable for non-smokers. In addition, all of these five miRNAs could differentiate NSCLC from controls with a higher accuracy in advanced stage and squamous carcinoma subgroups.
In conclusion, our study suggested that five plasma miRNAs (miR-20a, miR-145, miR-21, miR-223 and miR-221) can be used as promising biomarkers in early screening of NSCLC. Nevertheless, further validation and optimizing improvement should be performed on larger sample to confirm our results.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>25421010</pmid><doi>10.1186/s12931-014-0149-3</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1465-993X |
| ispartof | Respiratory research, 2014-11, Vol.15 (1), p.149-149, Article 149 |
| issn | 1465-993X 1465-9921 1465-993X 1465-9921 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4248445 |
| source | Open Access: PubMed Central; Springer Open Access; MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central Open Access; SpringerLink_现刊; Free E-Journal (出版社公開部分のみ） |
| subjects | Accuracy Analysis Area Under Curve Biological markers Biomarkers Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Cancer Carcinoma, Non-Small-Cell Lung - blood Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Care and treatment Case-Control Studies Cell growth Chronic obstructive pulmonary disease Comparative analysis Diagnosis Disease Double-Blind Method Female Gene Expression Profiling - methods Genetic Testing - methods Humans Lung cancer Lung cancer, Non-small cell Lung Neoplasms - blood Lung Neoplasms - genetics Lung Neoplasms - pathology Male Materials selection Medical imaging MicroRNA MicroRNAs MicroRNAs - blood MicroRNAs - genetics Middle Aged Mortality Neoplasm Staging Plasma Predictive Value of Tests Reproducibility of Results Risk Factors ROC Curve Studies Surgery Thoracic surgery |
| title | Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T09%3A33%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Five%20microRNAs%20in%20plasma%20as%20novel%20biomarkers%20for%20screening%20of%20early-stage%20non-small%20cell%20lung%20cancer&rft.jtitle=Respiratory%20research&rft.au=Geng,%20Qing&rft.date=2014-11-25&rft.volume=15&rft.issue=1&rft.spage=149&rft.epage=149&rft.pages=149-149&rft.artnum=149&rft.issn=1465-993X&rft.eissn=1465-993X&rft_id=info:doi/10.1186/s12931-014-0149-3&rft_dat=%3Cgale_pubme%3EA539614899%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1629479757&rft_id=info:pmid/25421010&rft_galeid=A539614899&rfr_iscdi=true |